Argeris N. Karabelas

CIK: 0001191229

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (42.9%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RGNX

REGENXBIO Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

RGNX
REGENXBIO Inc.
May 29, 2026
Award(A)
Direct
9.8K shares-
RGNX
REGENXBIO Inc.
May 30, 2025
Award(A)
Direct
7.8K shares-
RGNX
REGENXBIO Inc.
Oct 1, 2024
Exercise(M)
Direct
10K shares at avg. $3.76$38K
RGNX
REGENXBIO Inc.
Oct 1, 2024
Sale(S)
Direct
10K shares at avg. $10.11$101K
RGNX
REGENXBIO Inc.
Sep 3, 2024
Sale(S)
Direct
9.3K shares at avg. $11.50$107K
RGNX
REGENXBIO Inc.
Sep 3, 2024
Exercise(M)
Direct
10K shares at avg. $3.76$38K
RGNX
REGENXBIO Inc.
Sep 3, 2024
Sale(S)
Direct
700 shares at avg. $12.34$9K

		Type	Shares	Price		Ownership
May 29, 2026	RGNX REGENXBIO Inc.	Award(A)	9,807	-	$0	Direct
May 30, 2025	RGNX REGENXBIO Inc.	Award(A)	7,768	-	-	Direct
Oct 1, 2024	RGNX REGENXBIO Inc.	Exercise(M)	10,000	$3.76	$37,600	Direct
Oct 1, 2024	RGNX REGENXBIO Inc.	Sale(S)	10,000	$10.11	$101,052	Direct
Sep 3, 2024	RGNX REGENXBIO Inc.	Sale(S)	9,300	$11.50	$106,950	Direct
Sep 3, 2024	RGNX REGENXBIO Inc.	Exercise(M)	10,000	$3.76	$37,600	Direct
Sep 3, 2024	RGNX REGENXBIO Inc.	Sale(S)	700	$12.34	$8,638	Direct

1-7 of 7 transactions

About KARABELAS ARGERIS N

KARABELAS ARGERIS N (SEC CIK 0001191229) files insider reports with the SEC as Director of REGENXBIO Inc. (RGNX).

Signal8 holds 4 ownership filings by KARABELAS ARGERIS N, all Form 4s, filed between Sep 4, 2024 and Jun 2, 2026. Those filings report 7 transactions, from Sep 3, 2024 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on KARABELAS ARGERIS N's filings is in ROCKVILLE, MD.

Recent filings by KARABELAS ARGERIS N

May 29, 2026: Grant or award of RGNX shares (Form 4, code A).
May 30, 2025: Grant or award of RGNX shares (Form 4, code A).
Oct 1, 2024: Option exercise of RGNX shares (Form 4, code M).
Oct 1, 2024: Open-market sale of RGNX shares (Form 4, code S).
Sep 3, 2024: Open-market sale of RGNX shares (Form 4, code S).

Other insiders filing for REGENXBIO Inc. (RGNX)

Malzahn Craig, Chief Technology Officer
Christmas Patrick J., Chief Strategy & Legal Officer
PAKOLA STEVE, Chief Medical Officer
Chan Mitchell, Chief Financial Officer
Ciongoli Gregory Austin, Director
Simpson Curran, Chief Executive Officer

How to read Form 4 transaction codes